文献速递中枢神经肿瘤放疗放疗物理与技术

谷胱甘肽耗竭与微束放射治疗对荷晚期脑内F98肿瘤大鼠生存的影响:一项先导项目的结论

Survival of rats bearing advanced intracerebral F 98 tumors after glutathione depletion and microbeam radiation therapy: conclusions from a pilot project.
PubMed 文献 · Radiat Oncol · 2018-05-10

该先导项目在大鼠脑内F98胶质瘤晚期模型中,将谷胱甘肽合成抑制剂BSO注射与微束放射治疗(MRT)联合,发现联合组较单用MRT组生存时间显著延长;结论基于小样本先导实验。

要点

  • 在晚期脑内F98肿瘤大鼠中,MRT联合瘤内注射BSO较单用MRT显著延长平均生存时间。
  • 移植后30天,单用MRT组生存12.5%,联合BSO组生存62.5%。
  • 该结论来自先导项目的小样本动物实验,需进一步研究。

核心结论

  • 在该晚期恶性脑肿瘤原位小动物模型的先导项目中,注射谷胱甘肽抑制剂BSO联合MRT显著增加了平均生存时间。

研究设计与样本

  • 先导项目:将十万个F98胶质瘤细胞注入成年雄性Fischer大鼠右大脑半球,建立高度恶性脑肿瘤的晚期原位小动物模型。
  • 肿瘤细胞植入后第13天安排治疗,此时12.5%的动物已死于疾病,存活的24只荷瘤动物随机分为三组:A组单用MRT、B组MRT联合BSO、C组荷瘤未治疗对照。
  • 放疗动物中有一半在放疗前两小时接受瘤内注射100 μM BSO;另设与荷瘤动物治疗方式对应的无瘤动物。
  • MRT采用双向模式,准平行束阵列在肿瘤位置交叉,微束宽度约28 μm、中心间距约400 μm,峰值剂量350 Gy,正常组织谷剂量9 Gy、肿瘤位置谷剂量18 Gy,峰谷剂量比(PVDR)为31。

主要发现

  • 肿瘤细胞植入后,未治疗的荷瘤大鼠平均生存时间为15天。
  • 植入后20天,A组62.5%的动物和B组75%的大鼠仍存活。
  • 植入后30天,A组生存率为12.5%,B组为62.5%。
  • A组在第35天及以后无存活者,B组仍有25%存活。
  • 接受MRT联合辅助BSO注射的大鼠获得了最大的生存获益。

局限性

  • 原文结论标明该研究为先导项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to radiotherapy is frequently encountered in patients with glioblastoma multiforme. It is caused at least partially by the high glutathione content in the tumour tissue. Therefore, the administration of the glutathione synthesis inhibitor Buthionine-SR-Sulfoximine (BSO) should increase survival time. METHODS: BSO was tested in combination with an experimental synchrotron-based treatment, microbeam radiation therapy (MRT), characterized by spatially and periodically alternating microscopic dose distribution. One hundred thousand F98 glioma cells were injected into the right cerebral hemisphere of adult male Fischer rats to generate an orthotopic small animal model of a highly malignant brain tumour in a very advanced stage. Therapy was scheduled for day 13 after tumour cell implantation. At this time, 12.5% of the animals had already died from their disease. The surviving 24 tumour-bearing animals were randomly distributed in three experimental groups: subjected to MRT alone (Group A), to MRT plus BSO (Group B) and tumour-bearing untreated controls (Group C). Thus, half of the irradiated animals received an injection of 100 μM BSO into the tumour two hours before radiotherapy. Additional tumour-free animals, mirroring the treatment of the tumour-bearing animals, were included in the experiment. MRT was administered in bi-directional mode with arrays of quasi-parallel beams crossing at the tumour location. The width of the microbeams was ≈28 μm with a center-to-center distance of ≈400 μm, a peak dose of 350 Gy, and a valley dose of 9 Gy in the normal tissue and 18 Gy at the tumour location; thus, the peak to valley dose ratio (PVDR) was 31. RESULTS: After tumour-cell implantation, otherwise untreated rats had a mean survival time of 15 days. Twenty days after implantation, 62.5% of the animals receiving MRT alone (group A) and 75% of the rats given MRT + BSO (group B) were still alive. Thirty days after implantation, survival was 12.5% in Group A and 62.5% in Group B. There were no survivors on or beyond day 35 in Group A, but 25% were still alive in Group B. Thus, rats which underwent MRT with adjuvant BSO injection experienced the largest survival gain. CONCLUSIONS: In this pilot project using an orthotopic small animal model of advanced malignant brain tumour, the injection of the glutathione inhibitor BSO with MRT significantly increased mean survival time.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schültke E, Bräuer-Krisch E, Blattmann H, et al. Survival of rats bearing advanced intracerebral F 98 tumors after glutathione depletion and microbeam radiation therapy: conclusions from a pilot project. Radiat Oncol. 2018. PMID: 29747666. doi:10.1186/s13014-018-1038-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。